Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Eiger BioPharmaceuticals, Inc.EIGR · Entity 16554 | Director | March 01, 2023 | March 04, 2023 |
| VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875 | EVP Chief Patient & Ext Af Off | July 21, 2026 | July 23, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Eiger BioPharmaceuticals, Inc.
Report date March 01, 2023 · Filed March 04, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.71 · Expires 2033-02-28 | Direct | 28,000 |
Reported balance
After 2023-03-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-03-01 · Grant · Acquired 28,000 · Balance 28,000 F1: The option vests in equal monthly installments over 12 months measured from March 1, 2023, subject to Reporting Person's continuous service status as of each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in equal monthly installments over 12 months measured from March 1, 2023, subject to Reporting Person's continuous service status as of each such date.
VERTEX PHARMACEUTICALS INC / MA
Report date July 21, 2026 · Filed July 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 66,512 |
Reported balance
After 2026-07-21 transaction · row 1
1 source rowRow 1 · 2026-07-21 · Grant · Acquired 8,251 · Balance 66,512 F1: Restricted stock unit award that vests on 03/31/2030. |
| Common StockSEC Table I · non-derivative | Indirect401(k) | 882 |
Reported balance
Holding disclosure · report date 2026-07-21 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 882 |
| Common StockSEC Table I · non-derivative | IndirectHeld in Trust | 6,637 |
Reported balance
Holding disclosure · report date 2026-07-21 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 6,637 |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock unit award that vests on 03/31/2030.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 02, 2018 Filed Aug 6, 2018 22:19 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 300 | $179.38 | $53,814.00 |
DisclosureSEC source: 0001209191-18-045591 · doc4.xml · nonDerivative · entry 6 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,662 F1 · kind: Transaction made pursuant to Mr. Sachdev's company-approved trading plan under Rule 10b5-1. F7 · price: Open market sales reported on this line occurred at a weighted average price of $179.38 (range $179.17 to $179.49). Read SEC document |
| August 02, 2018 Filed Aug 6, 2018 22:19 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 355 | $178.49 | $63,363.95 |
DisclosureSEC source: 0001209191-18-045591 · doc4.xml · nonDerivative · entry 5 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,962 F1 · kind: Transaction made pursuant to Mr. Sachdev's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $178.49 (range $178.09 to $178.77). Read SEC document |
| August 02, 2018 Filed Aug 6, 2018 22:19 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 400 | $176.95 | $70,780.00 |
DisclosureSEC source: 0001209191-18-045591 · doc4.xml · nonDerivative · entry 4 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,317 F1 · kind: Transaction made pursuant to Mr. Sachdev's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $176.95 (range $176.62 to $177.21). Read SEC document |
| August 02, 2018 Filed Aug 6, 2018 22:19 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 400 | $175.88 | $70,352.00 |
DisclosureSEC source: 0001209191-18-045591 · doc4.xml · nonDerivative · entry 3 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,717 F1 · kind: Transaction made pursuant to Mr. Sachdev's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $175.88 (range $175.52 to $176.10). Read SEC document |
| August 02, 2018 Filed Aug 6, 2018 22:19 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 700 | $175.06 | $122,542.00 |
DisclosureSEC source: 0001209191-18-045591 · doc4.xml · nonDerivative · entry 2 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,117 F1 · kind: Transaction made pursuant to Mr. Sachdev's company-approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $175.06 (range $174.47 to $175.43). F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| August 02, 2018 Filed Aug 6, 2018 22:19 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 2,155 | $91.05 | $196,212.75 |
DisclosureSEC source: 0001209191-18-045591 · doc4.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,817 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 16, 2018 Filed Jul 17, 2018 22:30 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,719 | $0.00 Strike: $96.87 | $0.00 |
DisclosureSEC source: 0001209191-18-042903 · doc4.xml · derivative · entry 9 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,719 shares Expires 2024-07-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully vested. Read SEC document |
| July 16, 2018 Filed Jul 17, 2018 22:30 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 219 | $181.88 | $39,831.72 |
DisclosureSEC source: 0001209191-18-042903 · doc4.xml · nonDerivative · entry 5 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,662 F1 · kind: Transaction made pursuant to Mr. Sachdev's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $181.88 (range $181.65 - $181.93). Read SEC document |
| July 16, 2018 Filed Jul 17, 2018 22:30 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,500 | $180.14 | $270,210.00 |
DisclosureSEC source: 0001209191-18-042903 · doc4.xml · nonDerivative · entry 4 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,881 F1 · kind: Transaction made pursuant to Mr. Sachdev's company-approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $180.14 (range $180.00 - $180.66). F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| July 16, 2018 Filed Jul 17, 2018 22:30 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 1,719 | $96.87 | $166,519.53 |
DisclosureSEC source: 0001209191-18-042903 · doc4.xml · nonDerivative · entry 3 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,381 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 13, 2018 Filed Jul 17, 2018 22:30 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,031 | $0.00 Strike: $96.87 | $0.00 |
DisclosureSEC source: 0001209191-18-042903 · doc4.xml · derivative · entry 8 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,719 Underlying: Common Stock · 12,031 shares Expires 2024-07-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully vested. Read SEC document |
| July 13, 2018 Filed Jul 17, 2018 22:30 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 12,031 | $180.00 | $2,165,580.00 |
DisclosureSEC source: 0001209191-18-042903 · doc4.xml · nonDerivative · entry 2 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,662 F1 · kind: Transaction made pursuant to Mr. Sachdev's company-approved trading plan under Rule 10b5-1. Read SEC document |
| July 13, 2018 Filed Jul 17, 2018 22:30 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 12,031 | $96.87 | $1,165,442.97 |
DisclosureSEC source: 0001209191-18-042903 · doc4.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,693 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 29, 2018 Filed Jul 3, 2018 20:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,155 | $0.00 Strike: $91.05 | $0.00 |
DisclosureSEC source: 0001209191-18-040981 · doc4.xml · derivative · entry 8 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,086 Underlying: Common Stock · 2,155 shares Expires 2026-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vests in 16 quarterly installments from 2/2/2016. Read SEC document |
| June 29, 2018 Filed Jul 3, 2018 20:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,941 | $0.00 Strike: $86.52 | $0.00 |
DisclosureSEC source: 0001209191-18-040981 · doc4.xml · derivative · entry 7 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,358 Underlying: Common Stock · 1,941 shares Expires 2027-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vests in 16 quarterly installments from 2/3/2017. Read SEC document |
| June 29, 2018 Filed Jul 3, 2018 20:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,155 | $170.00 | $366,350.00 |
DisclosureSEC source: 0001209191-18-040981 · doc4.xml · nonDerivative · entry 4 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,662 F1 · kind: Transaction made pursuant to Mr. Sachdev's company-approved trading plan under Rule 10b5-1. Read SEC document |
| June 29, 2018 Filed Jul 3, 2018 20:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,941 | $165.00 | $320,265.00 |
DisclosureSEC source: 0001209191-18-040981 · doc4.xml · nonDerivative · entry 3 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,817 F1 · kind: Transaction made pursuant to Mr. Sachdev's company-approved trading plan under Rule 10b5-1. Read SEC document |
| June 29, 2018 Filed Jul 3, 2018 20:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 2,155 | $91.05 | $196,212.75 |
DisclosureSEC source: 0001209191-18-040981 · doc4.xml · nonDerivative · entry 2 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,758 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 29, 2018 Filed Jul 3, 2018 20:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 1,941 | $86.52 | $167,935.32 |
DisclosureSEC source: 0001209191-18-040981 · doc4.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,603 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2018 Filed May 16, 2018 21:06 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 83 | $155.78 | $12,929.74 |
DisclosureSEC source: 0001209191-18-030587 · doc4.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,662 F1 · kind: Transaction made pursuant to Mr. Sachdev's company-approved trading plan under Rule 10b5-1. Read SEC document |
| March 09, 2018 Filed Mar 12, 2018 21:36 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 13,750 | $0.00 Strike: $96.87 | $0.00 |
DisclosureSEC source: 0001209191-18-018919 · doc4.xml · derivative · entry 5 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,750 Underlying: Common Stock · 13,750 shares Expires 2024-07-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vests in 16 quarterly installments from 7/15/2014. Read SEC document |
| March 09, 2018 Filed Mar 12, 2018 21:36 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 13,750 | $175.00 | $2,406,250.00 |
DisclosureSEC source: 0001209191-18-018919 · doc4.xml · nonDerivative · entry 2 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,662 F1 · kind: Transaction made pursuant to Mr. Sachdev's company-approved trading plan under Rule 10b5-1. Read SEC document |
| March 09, 2018 Filed Mar 12, 2018 21:36 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 13,750 | $96.87 | $1,331,962.50 |
DisclosureSEC source: 0001209191-18-018919 · doc4.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,412 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 26, 2018 Filed Feb 28, 2018 14:30 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,155 | $0.00 Strike: $91.05 | $0.00 |
DisclosureSEC source: 0001209191-18-014341 · doc4.xml · derivative · entry 5 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,242 Underlying: Common Stock · 2,155 shares Expires 2026-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vests in 16 quarterly installments from 2/2/2016. Read SEC document |
| February 26, 2018 Filed Feb 28, 2018 14:30 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,155 | $170.00 | $366,350.00 |
DisclosureSEC source: 0001209191-18-014341 · doc4.xml · nonDerivative · entry 2 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,662 F1 · kind: Transaction made pursuant to Mr. Sachdev's company-approved trading plan under Rule 10b5-1. Read SEC document |
| February 26, 2018 Filed Feb 28, 2018 14:30 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 2,155 | $91.05 | $196,212.75 |
DisclosureSEC source: 0001209191-18-014341 · doc4.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,817 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 23:23 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 300 | $153.92 | $46,176.00 |
DisclosureSEC source: 0001209191-18-010146 · doc4.xml · nonDerivative · entry 6 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,662 F1 · kind: Transaction made pursuant to Mr. Sachdev's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F8 · price: Open market sales reported on this line occurred at a weighted average price of $153.92 (range $153.89 to $153.99). Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 23:23 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,400 | $153.25 | $214,550.00 |
DisclosureSEC source: 0001209191-18-010146 · doc4.xml · nonDerivative · entry 5 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,962 F1 · kind: Transaction made pursuant to Mr. Sachdev's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $153.25 (range $152.87 to $153.82). Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 23:23 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,100 | $152.26 | $167,486.00 |
DisclosureSEC source: 0001209191-18-010146 · doc4.xml · nonDerivative · entry 4 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,362 F1 · kind: Transaction made pursuant to Mr. Sachdev's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $152.26 (range $151.83 to $152.81). Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 23:23 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 7,296 | $151.22 | $1,103,301.12 |
DisclosureSEC source: 0001209191-18-010146 · doc4.xml · nonDerivative · entry 3 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,462 F1 · kind: Transaction made pursuant to Mr. Sachdev's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $151.22 (range $150.81 to $151.79). Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 23:23 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 3,200 | $150.44 | $481,408.00 |
DisclosureSEC source: 0001209191-18-010146 · doc4.xml · nonDerivative · entry 2 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,758 F1 · kind: Transaction made pursuant to Mr. Sachdev's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $150.44 (range $149.81 to $150.76). Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 23:23 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 4,500 | $149.22 | $671,490.00 |
DisclosureSEC source: 0001209191-18-010146 · doc4.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,958 F1 · kind: Transaction made pursuant to Mr. Sachdev's company-approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $149.22 (range $148.77 to $149.75). F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 06, 2018 Filed Feb 8, 2018 23:10 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option (Right to Buy) · Derivative | 23,479 | $0.00 Strike: $155.57 | $0.00 |
DisclosureSEC source: 0001209191-18-008531 · doc4.xml · derivative · entry 5 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,479 Underlying: Common Stock · 23,479 shares Expires 2028-02-05 F3 · derivative.exercise_date: This option vests in 16 quarterly installments from 2/6/2018. Read SEC document |
| February 06, 2018 Filed Feb 8, 2018 23:10 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 10,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-008531 · doc4.xml · nonDerivative · entry 2 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,458 F2 · shares: Restricted stock unit award that vests in three equal installments on 2/17/2019, 2/17/2020 and 2/17/2021. Read SEC document |
| February 06, 2018 Filed Feb 8, 2018 23:10 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 15,170 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-008531 · doc4.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,333 F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 2/3/2017 that contained both performance-vesting and service-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 2/6/2018. The earned performance shares remain subject to the service-vesting requirements and will vest in three equal installments on 2/10/2018, 2/10/2019 and 2/10/2020. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 23:26 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,578 | $0.00 Strike: $77.31 | $0.00 |
DisclosureSEC source: 0001209191-18-008227 · doc4.xml · derivative · entry 12 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,578 shares Expires 2024-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: Fully vested. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 23:26 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,942 | $0.00 Strike: $86.52 | $0.00 |
DisclosureSEC source: 0001209191-18-008227 · doc4.xml · derivative · entry 11 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,299 Underlying: Common Stock · 1,942 shares Expires 2027-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: The option vests in 16 quarterly installments from 2/3/2017. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 23:26 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,242 | $164.93 | $369,773.06 |
DisclosureSEC source: 0001209191-18-008227 · doc4.xml · nonDerivative · entry 8 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,163 F1 · kind: Transaction made pursuant to Mr. Sachdev's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F8 · price: Open market sales reported on this line occurred at a weighted average price of $164.93 (range $164.31 to $165.06). Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 23:26 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 600 | $163.79 | $98,274.00 |
DisclosureSEC source: 0001209191-18-008227 · doc4.xml · nonDerivative · entry 7 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,405 F1 · kind: Transaction made pursuant to Mr. Sachdev's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $163.79 (range $163.23 to $164.22). Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 23:26 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 300 | $161.93 | $48,579.00 |
DisclosureSEC source: 0001209191-18-008227 · doc4.xml · nonDerivative · entry 6 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,005 F1 · kind: Transaction made pursuant to Mr. Sachdev's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $161.93 (range $161.70 to $162.39). Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 23:26 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 300 | $160.97 | $48,291.00 |
DisclosureSEC source: 0001209191-18-008227 · doc4.xml · nonDerivative · entry 5 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,305 F1 · kind: Transaction made pursuant to Mr. Sachdev's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $160.97 (range $160.51 to $161.26). Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 23:26 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 700 | $159.93 | $111,951.00 |
DisclosureSEC source: 0001209191-18-008227 · doc4.xml · nonDerivative · entry 4 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,605 F1 · kind: Transaction made pursuant to Mr. Sachdev's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $159.93 (range $159.46 to $160.47). Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 23:26 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 378 | $158.55 | $59,931.90 |
DisclosureSEC source: 0001209191-18-008227 · doc4.xml · nonDerivative · entry 3 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,305 F1 · kind: Transaction made pursuant to Mr. Sachdev's company-approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $158.55 (range $158.24 to $159.09). F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 23:26 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 2,578 | $77.31 | $199,305.18 |
DisclosureSEC source: 0001209191-18-008227 · doc4.xml · nonDerivative · entry 2 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,683 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 23:26 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 1,942 | $86.52 | $168,021.84 |
DisclosureSEC source: 0001209191-18-008227 · doc4.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,105 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 29, 2018 Filed Jan 30, 2018 22:10 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,085 | $0.00 Strike: $91.05 | $0.00 |
DisclosureSEC source: 0001209191-18-006063 · doc4.xml · derivative · entry 5 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,397 Underlying: Common Stock · 15,085 shares Expires 2026-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vests in 16 quarterly installments from 2/2/2016. Read SEC document |
| January 29, 2018 Filed Jan 30, 2018 22:10 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 15,085 | $170.00 | $2,564,450.00 |
DisclosureSEC source: 0001209191-18-006063 · doc4.xml · nonDerivative · entry 2 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,163 F1 · kind: Transaction made pursuant to Mr. Sachdev's company-approved trading plan under Rule 10b5-1. Read SEC document |
| January 29, 2018 Filed Jan 30, 2018 22:10 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 15,085 | $91.05 | $1,373,489.25 |
DisclosureSEC source: 0001209191-18-006063 · doc4.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,248 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 23, 2018 Filed Jan 25, 2018 23:33 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,824 | $0.00 Strike: $86.52 | $0.00 |
DisclosureSEC source: 0001209191-18-005468 · doc4.xml · derivative · entry 5 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,241 Underlying: Common Stock · 5,824 shares Expires 2027-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vests in 16 quarterly installments from 2/3/2017. Read SEC document |
| January 23, 2018 Filed Jan 25, 2018 23:33 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 5,824 | $165.00 | $960,960.00 |
DisclosureSEC source: 0001209191-18-005468 · doc4.xml · nonDerivative · entry 2 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,163 F1 · kind: Transaction made pursuant to Mr. Sachdev's company-approved trading plan under Rule 10b5-1. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.